Home › Companies › United Therapeutics Corporation › 2025-2026

United Therapeutics Corporation 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and United Therapeutics Corporation’s Form 8-K (Item 5.07 on EDGAR). Page generated 04 October 2026.

18Reported items
708Asset managers
11,471Fund votes
2026-06-26Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore United Therapeutics Corporation in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by United Therapeutics Corporation

These tallies are United Therapeutics Corporation’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

United Therapeutics Corporation — official shareholder meeting results, meeting held 2026-06-26
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Christopher Causey	32,342,983	3,861,566	14,328	--	1,194,857	Majority: yes
Elect Director: Richard Giltner	33,029,828	3,174,662	14,387	--	1,194,857	Majority: yes
Elect Director: Ray Kurzweil	35,215,793	988,979	14,105	--	1,194,857	Majority: yes
Elect Director: Jan Malcolm	35,912,588	292,981	13,308	--	1,194,857	Majority: yes
Elect Director: Linda Maxwell	35,472,607	725,977	20,293	--	1,194,857	Majority: yes
Elect Director: Nilda Mesa	35,477,452	715,174	26,251	--	1,194,857	Majority: yes
Elect Director: Judy Olian	35,661,334	543,343	14,200	--	1,194,857	Majority: yes
Elect Director: Christopher Patusky	32,649,292	3,555,219	14,366	--	1,194,857	Majority: yes
Elect Director: Martine Rothblatt	34,492,974	1,713,789	12,114	--	1,194,857	Majority: yes
Elect Director: Louis Sullivan	33,409,607	2,794,332	14,938	--	1,194,857	Majority: yes
Elect Director: Tommy Thompson	35,012,786	1,192,155	13,936	--	1,194,857	Majority: yes
Elect Director: Kevin Tracey	36,187,554	18,239	13,084	--	1,194,857	Majority: yes
Proposal 2: An advisory resolution to approve executive compensation:	35,152,059	1,048,505	18,313	--	1,194,857	Majority: yes
Proposal 3: Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan:	25,872,075	10,070,290	276,512	--	1,194,857	Majority: yes
Proposal 4: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026:	35,753,887	1,647,415	12,432	--	--	Majority: yes

Source: United Therapeutics Corporation, Form 8-K — read the filing on EDGAR.

How asset managers voted at the United Therapeutics Corporation 2025-2026 meeting

Each item below shows how the 708 asset managers that disclosed a United Therapeutics Corporation vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of United Therapeutics Corporation’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Advisory resolution to approve executive compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 12 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,152,059AGAINST: 1,048,505

United Therapeutics Corporation’s own tally for this item (“Proposal 2: An advisory resolution to approve executive compensation:”): 35,152,059 for, 1,048,505 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 83% for, 2% against (85% of the company cast a for/against vote).

The 698 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 98%

FOR: 97.8%AGAINST: 2.2%ABSTAIN: 0.0%NOT VOTED: 0.0%SPLIT: 0.0%

Largest asset managers voting on “Advisory resolution to approve executive compensation.” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,415,002	2	For
BlackRock	4,821,983	293	For
Fidelity	2,013,301	0	For
Avoro Capital Advisors LLC	1,950,083	0	For
Wellington	1,702,773	0	For
State Street	1,662,081	0	For
Renaissance	1,297,762	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,228,214	0	For
Invesco	1,168,180	0	For
Janus Henderson	1,085,928	0	For
Charles Schwab	597,776	0	For
T. Rowe Price	560,792	22,410	For
ASSETMARK, INC	497,982	60	For
AQR	457,274	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	457,000	0	For
Northern Trust	377,333	0	For
Dimensional	338,044	0	For
MELLON INVESTMENTS Corp	329,823	0	For
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC	318,225	0	For
Swedbank Robur Fonder AB	314,514	0	For
BAILLIE GIFFORD OVERSEAS LTD	305,326	0	For
FULLER & THALER ASSET MANAGEMENT, INC.	284,237	0	For
Capitol Series Trust	275,236	0	For
LORD, ABBETT & CO. LLC	264,933	0	For
PICTET ASSET MANAGEMENT SA	259,314	0	For

Showing the 25 largest of 698 asset managers. See all 698 in the interactive database.

2. Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 6 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%AGAINST 28%

FOR: 25,872,075AGAINST: 10,070,290

United Therapeutics Corporation’s own tally for this item (“Proposal 3: Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan:”): 25,872,075 for, 10,070,290 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 61% for, 24% against (85% of the company cast a for/against vote).

The 182 asset managers below cast 87% of the shares they voted on this item FOR (13,356,958 for, 2,000,932 against).

FOR 86%13%

FOR: 13,356,958 (85.5%)AGAINST: 2,000,932 (12.8%)ABSTAIN: 257,948 (1.7%)NOT VOTED: 55 (0.0%)UNKNOWN: 7 (0.0%)

Largest asset managers voting on “Approval of the United Therapeutics Corporation 2026 Stock Incentive Plan.” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	5,080,806	557	1	For
BlackRock	2,961,581	0	0	For
Fidelity	1,456,281	60,390	0	For
Invesco	557,000	0	0	For
State Street	488,964	547	0	For
Charles Schwab	295,879	0	0	For
Capitol Series Trust	3,500	271,736	0	Against
Eversept Partners, LP	0	0	257,947	Abstain
Pacer Funds Trust	0	239,327	0	Against
Lord Abbett	230,372	0	0	For
First Trust	0	229,981	0	Against
JANUS INVESTMENT FUND	227,058	0	0	For
T. Rowe Price	215,343	7,100	0	For
Franklin Custodian Funds	200,000	0	0	For
Dimensional	0	177,305	0	Against
TIAA	155,920	0	0	For
Hartford	142,361	0	0	For
John Hancock	80,606	54,104	0	For
BOWEN HANES & CO INC	114,460	0	0	For
Thrivent	0	111,740	0	Against
JPMorgan	99,481	0	0	For
Jackson National	74,136	7,428	0	For
AQR	0	73,127	0	Against
ADVISORS SERIES TRUST	0	70,900	0	Against
TOCQUEVILLE ASSET MANAGEMENT L.P.	0	70,900	0	Against

Showing the 25 largest of 182 asset managers. See all 182 in the interactive database.

3. Election of Directors: Christopher Causey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 32,342,983AGAINST: 3,861,566

United Therapeutics Corporation’s own tally for this item (“Elect Director: Christopher Causey”): 32,342,983 for, 3,861,566 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 76% for, 9% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 94% of the shares they voted on this item FOR (14,349,078 for, 839,329 against).

FOR 94%

FOR: 14,349,078 (94.4%)AGAINST: 839,329 (5.5%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Christopher Causey” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,078,166	3,197	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	0	155,920	Against
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	7,428	74,136	Against
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

4. Election of Directors: Christopher Patusky

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 32,649,292AGAINST: 3,555,219

United Therapeutics Corporation’s own tally for this item (“Elect Director: Christopher Patusky”): 32,649,292 for, 3,555,219 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 77% for, 8% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 96% of the shares they voted on this item FOR (14,654,900 for, 533,506 against).

FOR 96%

FOR: 14,654,900 (96.4%)AGAINST: 533,506 (3.5%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Christopher Patusky” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,350	12	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

5. Election of Directors: Jan Malcolm

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%

FOR: 35,912,588AGAINST: 292,981

United Therapeutics Corporation’s own tally for this item (“Elect Director: Jan Malcolm”): 35,912,588 for, 292,981 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 85% for, 0.7% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.9% of the shares they voted on this item FOR (15,183,726 for, 4,681 against).

FOR 99.9%

FOR: 15,183,726 (99.9%)AGAINST: 4,681 (0.0%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Jan Malcolm” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,362	1	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,511	0	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

6. Election of Directors: Judy Olian

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 35,661,334AGAINST: 543,343

United Therapeutics Corporation’s own tally for this item (“Elect Director: Judy Olian”): 35,661,334 for, 543,343 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 84% for, 1% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.8% of the shares they voted on this item FOR (15,172,495 for, 15,912 against).

FOR 99.8%

FOR: 15,172,495 (99.8%)AGAINST: 15,912 (0.1%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Judy Olian” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,361	2	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

7. Election of Directors: Kevin Tracey

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 36,187,554AGAINST: 18,239

United Therapeutics Corporation’s own tally for this item (“Elect Director: Kevin Tracey”): 36,187,554 for, 18,239 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 85% for, 0.1% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.9% of the shares they voted on this item FOR (15,183,727 for, 4,680 against).

FOR 99.9%

FOR: 15,183,727 (99.9%)AGAINST: 4,680 (0.0%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Kevin Tracey” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Vote
Vanguard	5,081,363	For
BlackRock	2,961,581	For
Fidelity	1,516,671	For
Invesco	557,000	For
State Street	489,511	For
Charles Schwab	295,879	For
Capitol Series Trust	275,236	For
Pacer Funds Trust	239,327	For
Lord Abbett	230,372	For
First Trust	229,981	For
JANUS INVESTMENT FUND	227,058	For
T. Rowe Price	222,443	For
Franklin Custodian Funds	200,000	For
Dimensional	177,305	For
TIAA	155,920	For
Hartford	142,361	For
John Hancock	134,710	For
Thrivent	111,740	For
JPMorgan	99,481	For
Jackson National	81,564	For
AQR	73,127	For
ADVISORS SERIES TRUST	70,900	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	For
American Century	66,480	For
Equitable	66,260	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

8. Election of Directors: Linda Maxwell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 35,472,607AGAINST: 725,977

United Therapeutics Corporation’s own tally for this item (“Elect Director: Linda Maxwell”): 35,472,607 for, 725,977 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 84% for, 2% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.8% of the shares they voted on this item FOR (15,165,400 for, 23,007 against).

FOR 99.7%

FOR: 15,165,400 (99.8%)AGAINST: 23,007 (0.2%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Linda Maxwell” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,361	2	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,511	0	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

9. Election of Directors: Louis Sullivan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 33,409,607AGAINST: 2,794,332

United Therapeutics Corporation’s own tally for this item (“Elect Director: Louis Sullivan”): 33,409,607 for, 2,794,332 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 79% for, 7% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 97% of the shares they voted on this item FOR (14,672,000 for, 516,407 against).

FOR 97%

FOR: 14,672,000 (96.5%)AGAINST: 516,407 (3.4%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Louis Sullivan” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,352	11	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

10. Election of Directors: Martine Rothblatt

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 34,492,974AGAINST: 1,713,789

United Therapeutics Corporation’s own tally for this item (“Elect Director: Martine Rothblatt”): 34,492,974 for, 1,713,789 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 81% for, 4% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.6% of the shares they voted on this item FOR (15,132,770 for, 55,637 against).

FOR 99.5%

FOR: 15,132,770 (99.6%)AGAINST: 55,637 (0.4%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Martine Rothblatt” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,357	6	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	99,589	35,121	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

11. Election of Directors: Nilda Mesa

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 35,477,452AGAINST: 715,174

United Therapeutics Corporation’s own tally for this item (“Elect Director: Nilda Mesa”): 35,477,452 for, 715,174 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 84% for, 2% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.8% of the shares they voted on this item FOR (15,165,400 for, 23,007 against).

FOR 99.7%

FOR: 15,165,400 (99.8%)AGAINST: 23,007 (0.2%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Nilda Mesa” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,361	2	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,511	0	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

12. Election of Directors: Ray Kurzweil

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,215,793AGAINST: 988,979

United Therapeutics Corporation’s own tally for this item (“Elect Director: Ray Kurzweil”): 35,215,793 for, 988,979 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 83% for, 2% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.9% of the shares they voted on this item FOR (15,181,180 for, 7,227 against).

FOR 99.8%

FOR: 15,181,180 (99.9%)AGAINST: 7,227 (0.0%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Ray Kurzweil” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,359	4	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

13. Election of Directors: Richard Giltner

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 33,029,828AGAINST: 3,174,662

United Therapeutics Corporation’s own tally for this item (“Elect Director: Richard Giltner”): 33,029,828 for, 3,174,662 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 78% for, 7% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 96% of the shares they voted on this item FOR (14,653,012 for, 535,395 against).

FOR 96%

FOR: 14,653,012 (96.4%)AGAINST: 535,395 (3.5%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Richard Giltner” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,078,170	3,193	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	1,733	487,778	Against
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

14. Election of Directors: Tommy Thompson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,012,786AGAINST: 1,192,155

United Therapeutics Corporation’s own tally for this item (“Elect Director: Tommy Thompson”): 35,012,786 for, 1,192,155 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).

The 149 asset managers below cast 99.8% of the shares they voted on this item FOR (15,169,493 for, 18,914 against).

FOR 99.8%

FOR: 15,169,493 (99.8%)AGAINST: 18,914 (0.1%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Election of Directors: Tommy Thompson” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,081,359	4	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 149 asset managers. See all 149 in the interactive database.

15. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-06-26.

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 35,753,887AGAINST: 1,647,415

United Therapeutics Corporation’s own tally for this item (“Proposal 4: Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026:”): 35,753,887 for, 1,647,415 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 84% for, 4% against (88% of the company cast a for/against vote).

The 148 asset managers below cast 99.9% of the shares they voted on this item FOR (15,160,553 for, 12,048 against).

FOR 99.8%

FOR: 15,160,553 (99.9%)AGAINST: 12,048 (0.1%)ABSTAIN: 9,058 (0.1%)NOT VOTED: 55 (0.0%)

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Vanguard	5,078,175	3,188	For
BlackRock	2,961,581	0	For
Fidelity	1,516,671	0	For
Invesco	557,000	0	For
State Street	489,487	24	For
Charles Schwab	295,879	0	For
Capitol Series Trust	275,236	0	For
Pacer Funds Trust	239,327	0	For
Lord Abbett	230,372	0	For
First Trust	229,981	0	For
JANUS INVESTMENT FUND	227,058	0	For
T. Rowe Price	222,443	0	For
Franklin Custodian Funds	200,000	0	For
Dimensional	177,305	0	For
TIAA	155,920	0	For
Hartford	142,361	0	For
John Hancock	134,710	0	For
Thrivent	111,740	0	For
JPMorgan	99,481	0	For
Jackson National	81,564	0	For
AQR	73,127	0	For
ADVISORS SERIES TRUST	70,900	0	For
TOCQUEVILLE ASSET MANAGEMENT L.P.	70,900	0	For
American Century	66,480	0	For
Equitable	66,260	0	For

Showing the 25 largest of 148 asset managers. See all 148 in the interactive database.

16. Advisory resolution to approve executive compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-06-26 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 38,413,776AGAINST: 1,763,712

United Therapeutics Corporation’s own tally for this item (“Proposal 2: An advisory resolution to approve executive compensation:”): 38,413,776 for, 1,763,712 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 42,446,733 outstanding shares: 90% for, 4% against (95% of the company cast a for/against vote).

The 4 asset managers below cast 95% of the shares they voted on this item FOR (28,851 for, 1,456 against).

FOR 95%

FOR: 28,851 (95.2%)AGAINST: 1,456 (4.8%)

Largest asset managers voting on “Advisory resolution to approve executive compensation.” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Vote
Investment Management Corp of Ontario	17,467	0	For
GLENMEDE FUND INC	10,059	0	For
OSSIAM	0	1,456	Against
Philip James Wealth Mangement, LLC	1,325	0	For

17. Audit Related

AUDIT-RELATED

Meeting held 2026-06-26.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (53 for, 0 against).

FOR: 53 (100.0%)

Largest asset managers voting on “Audit Related” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Two Roads Shared Trust	42	0	0	0	For
Members Trust Co	11	0	0	0	For

18. Compensation

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-26.

97% Majority: yes · of votes cast

FOR 97%

FOR: 35,152,059AGAINST: 1,048,505

The 2 asset managers below cast 100% of the shares they voted on this item FOR (53 for, 0 against).

FOR 100%

FOR: 53 (100.0%)

Largest asset managers voting on “Compensation” at United Therapeutics Corporation, 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Two Roads Shared Trust	42	0	0	0	For
Members Trust Co	11	0	0	0	For

Largest United Therapeutics Corporation shareholders voting in 2025-2026

Ranked by the number of United Therapeutics Corporation shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 42,446,733 shares outstanding at the time of that meeting.

Top United Therapeutics Corporation shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	12.76%
2	BlackRock	11.36%
3	Fidelity	4.74%
4	Avoro Capital Advisors LLC	4.59%
5	Wellington	4.01%
6	State Street	3.92%
7	Renaissance	3.06%
8	GEODE CAPITAL MANAGEMENT, LLC	2.89%
9	Invesco	2.75%
10	Janus Henderson	2.56%

Reported United Therapeutics Corporation ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

United Therapeutics Corporation beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	12.72%	13F
Vanguard Group	9.84%	13F
Martine Rothblatt	6.76%	DEF14A
Avoro Capital Advisors LLC	6.74%	DEF14A
ROTHBLATT MARTINE A	5.50%	13G
Wellington Management	5.33%	13F
State Street	4.34%	13F
Renaissance Technologies	4.21%	13F
Citadel Advisors	1.64%	13F
Invesco	1.43%	13F

Percentages above are of 42,446,733 shares outstanding, as reported by United Therapeutics Corporation on its Form 10-Q dated 2026-04-29 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from United Therapeutics Corporation’s 10-Q dated 2026-04-29. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At United Therapeutics Corporation's shareholder meeting held 2026-06-26, in the 2025-2026 proxy season, 708 asset managers reported how they voted in their SEC Form N-PX filings, covering 11,471 separate fund positions. Their filings are grouped here into 18 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory resolution to approve executive compensation. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: United Therapeutics Corporation's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

United Therapeutics Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).